We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

12 hedge funds and large institutions have $31M invested in Krystal Biotech in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.77% less ownership

Funds ownership: 31.6% → 29.84% (-1.8%)

8% less funds holding

Funds holding: 13 → 12 (-1)

9% less capital invested

Capital invested by funds: $34M → $31M (-$3.01M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$739K
2
BlackRock
BlackRock
New York
+$65.4K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$18.4K
4
KBC Group
KBC Group
Belgium
+$12.1K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$2.01M
2
Goldman Sachs
Goldman Sachs
New York
-$232K
3
Squarepoint
Squarepoint
New York
-$114K
4
Millennium Management
Millennium Management
New York
-$79.6K

KRYS Hedge Fund Activity: Q1 2018 in Review

12 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2018, worth a combined $31M — down 8.8% from $34M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of KRYS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $739K. The largest seller was RA Capital Management, cutting an estimated $2.01M.

  • 12 institutional investors held Krystal Biotech (KRYS) as of Q1 2018, down from 13 in Q4 2017.
  • Funds reported $31M of Krystal Biotech stock for Q1 2018, down 8.8% quarter-over-quarter.
  • 1 fund opened new Krystal Biotech positions in Q1 2018 and 2 closed out, a net change of -1 holder.
  • The largest Krystal Biotech buyer in Q1 2018 was Vanguard Group, an estimated $739K added.
  • The largest Krystal Biotech seller in Q1 2018 was RA Capital Management, an estimated $2.01M sold.

Based on aggregated 13F filings for Q1 2018.